New Stock News | Acrobiosystems (301080.SZ) Plans Hong Kong IPO. The China Securities Regulatory Commission requires additional information on the overseas investment and regulatory procedures of overseas subsidiaries.

The China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issue and Listing (May 25, 2026-May 29, 2026)". The International Department of the China Securities Regulatory Commission issued supplementary materials requirements for 11 companies. Among them, Acrobiosystems (301080.SZ) is required to provide additional information on the specific fulfillment of overseas investments and foreign exchange management regulatory procedures by its overseas subsidiaries. According to the disclosure by the Hong Kong Stock Exchange on January 26, Beijing Acrobiosystems Biotechnology Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CMSC International as its exclusive sponsor. The China Securities Regulatory Commission requests Acrobiosystems to provide clarification on the following matters, and asks lawyers to verify and provide clear legal opinions: Please provide further details on the specific fulfillment of overseas investments, foreign exchange management, and other regulatory procedures by your company's overseas subsidiaries, and provide conclusive opinions on compliance. The prospectus shows that Acrobiosystems is a global provider of life science tools and technology services, dedicated to empowering biopharmaceutical companies across the full value chain of research and development, production, and clinical applications. Acrobiosystems offers a comprehensive product portfolio, integrating high-quality biological reagents (including recombinant proteins, antibodies, analytical test kits, and other products) and multiple technical services. The synergistic effects of the company's products enable it to provide one-stop solutions to meet the key needs of biopharmaceutical research and development from early target discovery to clinical trials. As of the final feasible date, the company offers over 5,000 product SKUs and a diverse range of technical service combinations, all produced or executed under strict international quality standards, including ISO 9001:2015, ISO 13485:2016, cGMP, MDSAP, CNAS, and Rx360.